Literature DB >> 7565665

Proteasome and class I antigen processing and presentation.

M P Belich1, J Trowsdale.   

Abstract

The recent discovery of two proteasome homologous genes, LMP2 and LMP7, in the class II region of the human MHC, has implicated this multi-subunit protease in an early step of the immune response; the degradation of intracellular and viral proteins. Short peptides produced by the proteasome are transported into the ER by the product of another set of MHC class II genes, TAP1 and TAP2, where they bind and stabilise HLA class I molecules. Antigenic peptides displayed at the cell surface by HLA class I molecules mark cells for destruction by cytotoxic T lymphocytes. The role of the proteasome in antigen processing was questioned when mutant cells, which lack the LMP genes, were able to process and present antigens normally. The discovery that two proteasome beta-subunits, delta and MB1, highly homologous to LMP2 and LMP7 and expressed in reciprocal manner, is now consistent with a role for the proteasome in antigen processing. The incorporation of different beta-subunits into the proteasome may be a mechanism to modulate catalytic activity of the proteasome complex, allowing production of peptides that are more suitable to enter into the ER by the TAP transporters and to bind HLA class I molecules. But, in the absence of the LMPs, the other subunits permit processing of most antigens reasonably efficiently.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565665     DOI: 10.1007/BF00990971

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  39 in total

1.  Antigen processing. Transporters of delight.

Authors:  P Parham
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

3.  Identification of self peptides bound to purified HLA-B27.

Authors:  T S Jardetzky; W S Lane; R A Robinson; D R Madden; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

4.  Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.

Authors:  F Momburg; V Ortiz-Navarrete; J Neefjes; E Goulmy; Y van de Wal; H Spits; S J Powis; G W Butcher; J C Howard; P Walden
Journal:  Nature       Date:  1992-11-12       Impact factor: 49.962

5.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.

Authors:  M Gaczynska; K L Rock; A L Goldberg
Journal:  Nature       Date:  1993-09-16       Impact factor: 49.962

6.  MHC-linked LMP gene products specifically alter peptidase activities of the proteasome.

Authors:  J Driscoll; M G Brown; D Finley; J J Monaco
Journal:  Nature       Date:  1993-09-16       Impact factor: 49.962

7.  H-2-linked low-molecular weight polypeptide antigens assemble into an unusual macromolecular complex.

Authors:  J J Monaco; H O McDevitt
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

8.  The LMP antigens: a stable MHC-controlled multisubunit protein complex.

Authors:  J J Monaco; H O McDevitt
Journal:  Hum Immunol       Date:  1986-04       Impact factor: 2.850

9.  Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins.

Authors:  M P Belich; R J Glynne; G Senger; D Sheer; J Trowsdale
Journal:  Curr Biol       Date:  1994-09-01       Impact factor: 10.834

10.  Folding and assembly of major histocompatibility complex class I heterodimers in the endoplasmic reticulum of intact cells precedes the binding of peptide.

Authors:  J J Neefjes; G J Hämmerling; F Momburg
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Relationships between proteasomes and viral gene products.

Authors:  A S Jarrousse; K Gautier; S Apcher; S Badaoui; G Boissonnet; M H Dadet; L Henry; J P Bureau; H P Schmid; F Petit
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

2.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

3.  Involvement of proteasomal subunits zeta and iota in RNA degradation.

Authors:  F Petit; A S Jarrousse; B Dahlmann; A Sobek; K B Hendil; J Buri; Y Briand; H P Schmid
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

Review 4.  Proteasome (prosome) associated endonuclease activity.

Authors:  F Petit; A S Jarrousse; G Boissonnet; M H Dadet; J Buri; Y Briand; H P Schmid
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

Review 5.  Antigen processing by proteasomes: insights into the molecular basis of crypticity.

Authors:  H Djaballah
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

6.  Comparative genomic analysis of the proteasome β5t subunit gene: implications for the origin and evolution of thymoproteasomes.

Authors:  Yoichi Sutoh; Mizuho Kondo; Yuko Ohta; Tatsuya Ota; Utano Tomaru; Martin F Flajnik; Masanori Kasahara
Journal:  Immunogenetics       Date:  2011-07-07       Impact factor: 2.846

7.  Mov34 protein from mouse brain interacts with the 3' noncoding region of Japanese encephalitis virus.

Authors:  M Ta; S Vrati
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.

Authors:  T W Tobery; R F Siliciano
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.